Introduction. The awareness of the incidence and timing of postpartum venous thromboembolic events guides the use of thromboprophylaxis. Our aims were to assess the incidence and mortality of venous thromboembolic events and identify its associated risk factors during different postpartum periods. Material and methods. A population-based controlled cohort study by combining four large registers in [2001][2002][2003][2004][2005][2006][2007][2008][2009][2010][2011]. All women with a recent delivery were identified. The incidence, risk factors and mortality of venous thromboembolic events 0-180 days after delivery were assessed by using all healthy delivered women as the control group. The incidence was compared with that of the nonpregnant women. Results. Among the 634 292 delivered women, 1169 had venous thromboembolic events 0-180 days postpartum. The incidence of venous thromboembolic events was highest during the first week postpartum: 37-fold compared with nonpregnant women, declining to two-fold immediately after that. Almost half of the venous thromboembolic events occurred between 43 and 180 days postpartum. The incidence of venous thromboembolic events was four-fold compared with that of nonpregnant women. Three venous thromboembolic events-related deaths occurred. Older age, higher body mass index, thrombophilia, multiple pregnancy, gestational diabetes, anemia, chorioamnionitis, threatening premature birth, in vitro fertilization with ovarian hyperstimulation, primiparity, cesarean section, cardiac/renal diseases, and varicose veins were associated with an increased risk for postpartum venous thromboembolic events. The risk remained elevated for 180 days in women with thrombophilia, cesarean section, multiple pregnancy, varicose veins, and cardiac disease. Conclusions. The risk of venous thromboembolic events remained elevated compared with that of the nonpregnant women after the usually defined postpartum period (6 weeks). The results might assist in selecting women in need of thromboprophylaxis.
Introduction
Venous thromboembolic event (VTE) is a serious maternal complication that is one of the leading causes of maternal death and mortality in the western world (1) . The hypercoagulative state is at its highest during delivery and immediately postpartum to prepare the parturient for the hemostatic challenges of delivery (2) . Most of the previous studies document that VTE occurs most likely during the postpartum period (3) (4) (5) (6) . A 30-year population-based study documented five-fold VTE incidence in puerperium compared with that of the antepartum period (7) . The incidence of VTE has been reported to be highest immediately after childbirth (8) .
Recent guidelines for the treatment and prevention of obstetrics-associated VTE summarize the relevant recommendations (9) . They recommend 6 weeks postpartum low-molecular-weight heparin (LMWH) prophylaxis for those with combined thrombophilia, homozygous factor V Leiden mutation or prothrombin gene variant, antithrombin deficiency, antiphospholipid antibodies, previous episode of VTE regardless of predisposing factor or thrombophilia status. These guidelines list several risk factors that predispose women to postpartum VTE, such as cesarean section, age >35 years, body mass index (BMI) ≥30 kg/m 2 , strict bed rest before delivery combined with BMI ≥25 kg/m 2 , postpartum hemorrhage or infection, preeclampsia, smoking, BMI ≥ 30 kg/m 2 , and anemia. The guidelines recommend considering 10 days to 6 weeks LMWH prophylaxis depending on the absolute VTE risk for each risk factor, the number of simultaneous risk factors and persistency of particular risk factors. Our thromboprophylaxis practices in Finland follow these recommended ones. It is not well-known which of these risk factors are high enough risks to warrant prolonged postpartum thromboprophylaxis and how combinations of independent risk factors affect overall VTE risk (10) .
Very few studies (8, 11) report the VTE incidence longer than through 12 weeks, so it is still unclear when the VTE risk returns to baseline. Moreover, only one study assesses the risk of VTE during specific postpartum periods (12) . More information about VTE incidence and risk factors during specific postpartum periods could benefit clinicians with the decisions regarding the optimal duration of postpartum LMWH prophylaxis in specific risk groups.
The aims of our study were first, to calculate the cumulative and weekly incidence of VTE through 180 postpartum days; second, to identify the associated risk factors during four different postpartum periods and assess the mortality for postpartum VTE; and third, to compare the incidence of postpartum VTE with that of the population of nonpregnant women of fertile age.
Material and methods

Registers
We performed a population-based cohort study by using combined data from the Care Register for Health Care (HILMO), the National Medical Birth Register, the Register of Induced Abortions, Cause of Death Register and Population Register Center for the years 2001-2011. The three first registers are maintained by the National Institute for Health and Welfare, which also gave the approval to use their register data in this study. The Cause of Death Register is maintained by Statistics Finland (13) . No ethical committee statement was required because the study was performed with anonymous register data and no registered person was contacted.
The HILMO Register contains details of all hospital inpatient admissions and public hospital outpatient admissions nationwide, along with information on discharge diagnoses, which are coded using the 10th version of the International Classification of Diseases (ICD-10). All diagnoses within the hospitalization period are recorded within episodes (time period under a particular consultant).
The Medical Birth Register contains information on all live births and stillbirths with a gestational age of ≥22 weeks or with a birthweight of ≥500 g from all delivery units in Finland. Planned home births and unplanned births outside hospitals are reported separately with a data collection form. The National Medical Birth Register also contains information on the mother's demographic data during pregnancy and labor, interventions and ICD-10 diagnoses during pregnancy and puerperium through 7 days after the delivery and the child's health data up to 7 days age.
Key Message
The risk of a venous thromboembolic event was 37 times higher during the first week after delivery and two times higher between 7 and 175 days postpartum compared with that in nonpregnant women. The most important risk factors were high age, thrombophilia, cesarean section, obesity, chorioamnionitis, cardiac disease, varicose veins, and in vitro fertilization with ovarian hyperstimulation syndrome.
Information on the deaths is derived from the Cause of Death Register. To determine the nonpregnant fertileaged population we used the data on the total 15-to 49-year-old female population taken from Population Register Center combined with the data of the Medical Birth Register and the Register of Induced Abortions. The Register of Induced Abortions collects information on all induced abortions, collected from obligatory notifications from hospitals performing them. The data collection form includes information on the woman's social and reproductive background, the indication(s) for the abortion, the procedure used, and early complications (14) .
Population
The date of delivery was obtained from the Medical Birth Register. Those women with an inpatient or outpatient admission after the date of delivery with a diagnosis of VTE were collected from HILMO. Women with an ICD-10 code (used in Finland from year 1996) of deep venous thrombosis (DVT) (I80.1-I80.9), portal vein thrombosis (I82.0-I82.9), pulmonary embolism (PE) (I26.0, I26.9) and VTE specifically related to postpartum or delivery (O87.1 and O88.2) were included. Each woman with a VTE diagnosis is included in only one group, either DVT or PE, depending on the primary diagnosis. Hence, women with PE can have DVT as the secondary diagnosis. Women were identified by using their personal identification number to avoid double recognition, as some patients were admitted more than once with the same VTE diagnosis. The women were divided into six different age groups: below 20, 20-24, 25-29, 30-34, 35-39 and ≥40 years (age at the day of childbirth). Cumulative incidence of total VTEs, DVT (I80.1-9, I82.0-9 and O87.1) and PE (I26.0, I26.9 and O88.2) were defined separately in each age group.
The possible risk factors for postpartum VTE were studied using women having delivered between 2001 and 2011 without postpartum VTE as a control group. VTE diagnoses of all nonpregnant 15-to 49-year-old women coded in HILMO were used to determine the baseline incidence of VTE in the years 2001-2011.
Variables
Medical conditions, which were recorded before pregnancy or during pregnancy (if pregnancy-associated) were identified from HILMO and the Medical Birth Register. The following medical conditions were available in HILMO for the whole period of this study ( For analyzing whether the risk factors of VTE differed during the specified postpartum periods, we quantified the medical conditions by the first postpartum week (0-6 days), early postpartum (0-21 days), mid postpartum (22-42 days) and late postpartum (43-180 days).
Outcome
The cumulative incidence of VTE during 180 days among postpartum women was calculated by dividing the number of postpartum VTE diagnoses by the total number of deliveries. The weekly incidence of postpartum VTE was identified through 180 postpartum days. The cumulative baseline incidence of VTE for years 2001-2011 was calculated from the total number of 15-to 49-year-old women in the population consisting of women who did not have a pregnancy ending at birth or induced abortion in the same calendar year. Pregnancies ending in a miscarriage or ectopic pregnancy were not available, since complete information on these cases was not available. The incidence of VTE in the nonpregnant female population was investigated by defining the amount of VTEs per 10 000 women per day and multiplying that by 180 to obtain a cumulative incidence for 180 days nonpregnant time-period.
Statistical analyses
Multivariable logistic regression with 95% CI were used to evaluate the factors associated with postpartum VTE risk. All models were adjusted for maternal age, the year of the delivery and thrombophilia. Selected variables were adjusted also by BMI or number of fetuses, depending on its relevance to the variable. The statistical software package SAS 9.3 (SAS Institute, Cary, NC, USA) was used for data analysis.
Results
Between 2001 and 2011 634 292 deliveries were registered. Postpartum VTE was diagnosed in 1169 women during the days 0-180, from which 904 were DVTs and 265 PE or both. The average nonpregnant 15-to 49-yearold female population included 1 232 841 women with 13.56 million women-years in 2001-2011.
The cumulative incidence of postpartum VTE was 18.4 per 10 000 deliveries, whereas it was 4.7 per 10 000 nonpregnant women during the 180 days. Number and incidence of VTE diagnoses by postpartum days are shown in Table 1 . The incidence was highest during the first week postpartum: 6.7 per 10 000 deliveries declining immediately after that. A total of 498 VTEs occurred during days 0-21 (43%), 107 (9%) during days 22-42, and 564 (48%) during days 43-180. The weekly incidence of VTE in nonpregnant women of fertile age was 0.18 per 10 000, which indicates that the incidence of VTE remained at least two-fold higher through 175 days after the delivery. The incidence of VTE was 0.22 per 10 000 deliveries during days 175-180, which is near the baseline incidence of non-pregnant women.
The incidence of postpartum VTE increased by age from 10.0 per 10 000 deliveries for women aged 15-19 years to 42.6 per 10 000 deliveries for women aged 40-49 years (Table 2) .
We observed the association between selected chronic diseases, pregnancy-related conditions, and delivery complications and the occurrence of postpartum VTE (Tables 3 and 4) . Diagnosis codes for thrombophilia were registered in HILMO in 54 (4.6%) women with postpartum VTE and in 1363 (0.2%) women without it. Our results show that the conditions associated with postpartum VTE were thrombophilia, multiple pregnancy, varicose veins, cesarean section, IVF pregnancy with OHSS, primiparity, obesity, gestational diabetes, chronic hypertension, cardiac or renal disease, anemia, chorioamnionitis, threatening premature birth (usually demanding strict bed rest), and preeclampsia.
When the risk factors were quantified for the different postpartum periods, the vast majority of those VTEs that occurred during 0-21 days postpartum occurred actually during the first 0-6 postpartum days. For women with thrombophilia, cesarean delivery, multiple pregnancy, varicose veins, or cardiac disease the risk of VTE remained elevated up to 180 days postpartum. For women with IVF pregnancy and OHSS, BMI ≥ 30 kg/m 2 , or chorioamnionitis the risk of VTE was increased until 42 days postpartum. For women with threatened premature birth, renal disease, anemia, and BMI ≥ 25 kg/m 2 the risk of VTE was elevated only for the first 21 days postpartum. VTE risk was elevated for the first 0-6 days after childbirth for those with pre-eclampsia.
Percentage of delivered women with postpartum VTE as a function of time (weeks) is shown in Figure 1 .
Three deaths related to postpartum VTE occurred in Finland between 2001 and 2011: all with an ICD-10 diagnosis O88.2 (PE). The total case-fatality rate was 2.6 per 1000 VTEs.
Discussion
The cumulative incidence of postpartum VTE was 18.4 per 10 000 deliveries during the first 180 postpartum days, which is somewhat lower compared with a previous report from the UK with the incidence of 22.8 per 10 000 deliveries/6 months (3), but higher than in most other reports with incidence rates between 4 and 10 per 10 000 deliveries (4, 5, 15, 16) . The lower incidence rates can reflect real differences but also less complete data, especially if multiple data sources and register linkages could not have been used. The length of follow-up period was taken into account in the comparison of our results with the previously published ones for studies for which the follow-up period is known. Our main result was the finding that the incidence of postpartum VTE remained at least two-fold through 175 postpartum days compared with that of nonpregnant women of fertile age and 48% of VTEs occurred after 42 postpartum days. It is in line with the study by Roeters van Lennep et al. (17) in which 40% of VTEs occurred later than 6 weeks after delivery in the women with high risk of VTE, when LMWH prophylaxis was already discontinued.
Our findings are also in line with a recent study, in which the risk of VTE was highest during the first postpartum week (9 per 10 000 deliveries) decreasing to 1 per 10 000 deliveries in the fourth postpartum week and continued to decrease steadily through the 12th week (18) .
The crossover-cohort study by Kamel et al. (11) reported that the risk of VTE during the first 6-week period after the delivery was 11-fold compared with the corresponding 6-week period 1 year later and two-fold during the second 6-week period (7-12 weeks) compared with the same time periods 1 year later. Our findings are similar, but we also found increased VTE risk beyond postpartum week 12.
According to our findings the risk of postpartum VTE increased with older age and higher BMI. The increased incidences in older women, however, might be the result of other factors, such as obesity and pregnancy complications. The medical conditions associated with an increased risk for postpartum VTE were thrombophilia, multiple pregnancy, gestational diabetes, anemia, chorioamnionitis, threatening premature birth, IVF pregnancy with OHSS, primiparity, cesarean section, cardiac or renal disease, and varicose veins associated with an increased risk for postpartum VTE. The risk of VTE remained elevated through 180 postpartum days in women with thrombophilia, cardiac disease, varicose veins, cesarean section, and multiple pregnancy. It should be recognized, that a significant amount of women with multiple pregnancies could have had cesarean sections. Many of our findings concerning the risk factors are similar to those published by others (5, 15, 19) , although risk factors observed differentiated between these studies. Postpartum hemorrhage has previously been reported to be a risk factor for postpartum VTE (3, 15, 18) . We, however, do not find evidence for this in our study. One explanation for this might be the anticoagulation used by the women with postpartum hemorrhage. We should however recognize, that diagnosed anemia, which associated with an increased risk for postpartum VTE, might be due to postpartum hemorrhage. The study by Sultan et al. (12) suggest that the duration of the increased VTE risk after delivery varies based on the type of risk factors. In their study the VTE risk remained elevated for 6 weeks in women with preeclampsia, BMI > 30 kg/m 2 , infection, and cesarean section. These findings are in line with our results, except for preeclampsia, which we found to be associated only for the first weeks' elevated VTE risk.
The population-based design with almost 635 000 deliveries and the combined data of national mandatory registers were the ultimate strengths of our study. In Finland where the population is small with 5.5 million citizens, researchers are privileged to have the possibility to use unique nationwide registers, which are maintained carefully according to the precise instructions by medical authorities. The general completeness and validity of diagnosis coding of the Medical Birth Register and HILMO has been shown to be good (20, 21) . Generally, >95% of discharges could be identified from the HILMO with positive predictive value for common diagnoses 75-99% (20) . Our registers allow us to use existing register data on the total population, which improves the reliability of the analysis. As far as we know there are few previously published studies of postpartum VTE incidence with long follow-up time (≥6 months) (8, 11) . We also believe that our study supports the previous studies, which directly compare the incidence of VTE in puerperal women with that of women outside pregnancy or puerperium (7, 8, 11, 22) . Only one previous study has been published on the risk of VTE during specific postpartum periods (12) . Our study therefore contributes to knowledge on the duration of elevated risk of VTE in association with different risk factors.
The limitations of our study have to be acknowledged. Because our data are limited to information derived from hospital discharge recordings from HILMO, detailed information is not available if VTEs are diagnosed accurately by imaging. The availability of imaging modalities in different hospitals might also vary, so some cases may go undiagnosed. Because data were retrieved only from specialized health care (inpatient and outpatient hospital care), some patients with mild symptoms might have been diagnosed and treated in primary care, leading us to underestimate the real VTE incidence. When evaluated during outpatient visits women with mild symptoms could have been diagnosed first as VTE, but this may later have been ruled out after further examinations, leading us to overestimate the real VTE incidence. Because the proportion of women with prescribed thromboprophylaxis is not known, it is possible that women with known thrombophilia and other strongest recognized risk factors (before VTE) may have already been anticoagulated, which might bias the analysis. Only 4.6% of women with postpartum VTE had a diagnosis of thrombophilia in HILMO, which is significantly less than in a previous study where the prevalence of inherited thrombophilia was 20-50% in pregnant or puerperal women with VTE (23) . As the laboratory tests for thrombophilia are usually taken 2-3 months after the hospital discharge, it is possible that diagnosis of thrombophilia is not coded accurately in the medical records during subsequent outpatient visits or phone contact. The fact that the individuals have been tested only for instance due to previous VTE or VTE in their families might explain our low percentage of thrombophilia (0.2%) in women without postpartum VTE. This percentage is less than the observed prevalence of Factor V Leiden mutation in Finland (2-3%) in pregnant women (24) and the prevalence of 10% of any inherited or acquired thrombophilia in generally (25, 26) . Hence, the VTE risk for thrombophilia might be overestimated in our study. In addition, we were unable to examine the effect of ethnicity on the VTE incidence due to the restrictions to gather such information in the Finnish health registers. The information of possible previous VTE was not available, which is previously found to associate significantly with the risk of postpartum VTE.
Based on our findings we conclude that the risk for postpartum VTE is highest during the first week after delivery and declines rapidly after that, but a two-fold residual risk remains in comparison with nonpregnant women up to 175 days postpartum. The risk of postpartum VTE increased significantly with older age and higher BMI. The most important specified risk factors for postpartum VTE were thrombophilia, varicose veins, multiple pregnancy, chorioamnionitis, IVF pregnancy with OHSS, cesarean section, and cardiac or renal diseases. Pregnancies complicated by any or a combination of these factors require careful consideration in terms of VTE risk during the immediate postpartum. In addition to thrombophilia and previous VTE, clinicians usually initiate LMWH prophylaxis for those with cesarean section if other specified simultaneous risk factors exist. Based on our findings the risk for postpartum VTE is also high associated with other conditions, especially chorioamnionitis, varicose veins, multiple pregnancy, and IVF pregnancy with OHSS. Hence, postpartum LMWH prophylaxis (7-10 days) for these cases could be considered, even after vaginal delivery -especially if other simultaneous risk factors exist. Multi-professional cooperation is required for the management of women with cardiac and renal diseases, which are not common among women of fertile age. However, we have to be cautious in drawing too precise conclusions based on this directional register data. Further studies about the optimal dosing and duration of LMWH prophylaxis in association with the above-mentioned risk factors are still called for.
